Skip to main content

Table 1 Clinical characteristics of the patients from multiple institutions

From: m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer

Characteristics

International cohort (N = 68)

Shanghai cohort (N = 47)

NCC cohort (N = 150)

Age, years

 < 60

16 (23.53%)

26 (55.32%)

81 (54.00%)

 ≥ 60

52 (76.47%)

21 (44.68%)

69 (46.00%)

Sex

 Male

48 (70.59%)

42 (89.36%)

119 (79.33%)

 Female

20 (29.41%)

5 (10.64%)

31 (20.67%)

Smoking history

 Yes

64 (94.12%)

32 (68.09%)

94 (62.67%)

 No

3 (4.41%)

15 (31.91%)

56 (37.33%)

 NA

1 (1.47%)

0 (0.00%)

0 (0.00%)

SCLC staging

 I

33 (48.53%)

8 (17.02%)

49 (32.67%)

 II

14 (20.59%)

39 (17.02%)

50 (33.33%)

 III

21 (30.88%)

31 (65.96%)

51 (34.00%)

OS state

 Alive

28 (41.18%)

24 (51.06%)

69 (46.00%)

 Death

40 (58.82%)

23 (48.94%)

81 (54.00%)

  1. Data are n (%).
  2. NCC, National Cancer Center; NA, not available; SCLC, small cell lung cancer; OS, overall survival